Silence Therapeutics Plc ADR (SLN) Implied Volatility Current

Tracking SLN implied volatility helps you identify when options premiums on Silence Therapeutics Plc ADR are historically cheap or expensive, and where the best trades are hiding. Silence Therapeutics Plc ADR implied volatility reflects the market's expectation of future price movement: when SLN IV rises, option premiums increase, creating opportunities for sellers, and when it drops, buyers can find cheaper contracts. Use our scanner to monitor Silence Therapeutics Plc ADR's implied volatility current levels in real time and filter for high-probability trades.

Implied volatility is derived from option prices using models like Black-Scholes and represents the annualized expected move of an underlying stock. For SLN, tracking metrics like SLN IV rank helps traders understand whether current implied volatility is historically high or low. IV rank compares today's reading against the past year's range — a high rank on SLN signals rich premiums and potential mean-reversion, while a low rank may favor long options strategies.

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver. It designs short interfering RNA molecules to harness the body's natural mechanism of RNA interference, and degrading messenger RNA molecules that encode specific targeted disease-associated proteins in a cell. The company is developing various product candidates, including SLN360, which is Phase I clinical trials for the treatment of cardiovascular disease with high lipoprotein; SLN124 that is in Phase I clinical trials for the treatment of non-transfusion dependent thalassemia, and Phase I clinical trials for the treatment of myelodysplastic syndrome; and SLN124 for the treatment of polycythemia vera.

It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize small interfering RNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company also has a collaboration with Hansoh Pharmaceutical Group Company Limited to develop siRNAs for three undisclosed targets leveraging Silence's mRNAi GOLD platform. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc is headquartered in London, the United Kingdom.

Premium sellers, directional traders, and spread builders all need the same starting point: a clear read on where SLN implied volatility sits today versus where it has been. Our scanner ranks Silence Therapeutics Plc ADR implied volatility against its historical range, surfaces extremes in SLN IV rank, and pairs every reading with the trades that exploit it. Stop guessing whether Silence Therapeutics Plc ADR IV is rich or cheap — measure it, then act on it.